SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY
SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.
Read the full articleYou might also wanna read
Sellas Life Sciences Aktie: 78 von 80 Events vor Daten-Lock
Sellas Life Sciences steht unmittelbar vor einem klinischen Meilenstein. Die entscheidende Studie des wichtigsten Krebsimpfstoffs erreicht f
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK & Genmab announced submission of MAA to EMEA for Arzerra, treatment of CLL, it targets a binding site on the CD20 molecule of B-cells.
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
GSK & GEN announced submission of BLA to the FD) for Arzerra to treat patients whose CLL is resistant (refractory) to previous therapies.
A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
Conditions : Myelodysplastic Syndromes; Beta-thalassemia Interventions : Drug: Luspatercept Sponsors : Bristol-Myers Squibb Terminated
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Conditions : PIK3CA-Related Overgrowth Spectrum (PROS); Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutatio
ABL Bio doubles down on self-sustainable growth beyond licensing deals
ABL Bio is seeking to transform itself from a licensing-focused biotech company into a globally competitive drug developer while advancing b
Comments
Sign in to join the conversation.
No comments yet. Be the first.